CAC Software vs AVIEW

Direct competitors — feature-level head-to-head below. Comparability 90/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Imbio
VS
by Coreline Soft Co.

AI Verdict

Tool A is a specialized solution focused exclusively on coronary artery calcification (CAC) analysis from CT scans. Tool B is a comprehensive AI platform that includes robust coronary artery calcification scoring as a key feature, alongside extensive capabilities for lung cancer, COPD, and other pulmonary conditions. Therefore, while both tools directly compete in the domain of CAC scoring, Tool B offers a broader diagnostic suite encompassing both cardiac and pulmonary imaging.

Choose CAC Software if…

Choose Imbio's CAC Software if your primary need is a highly focused, automated solution for precisely quantifying coronary artery calcification from non-contrast chest CT scans. This tool is ideal for cardiologists and radiologists seeking detailed Agatston scores, arterial age, and calcified lesion metrics specifically for coronary artery disease risk assessment within their existing DICOM workflow.

View CAC Software →

Choose AVIEW if…

Choose Coreline Soft's AVIEW if you require a comprehensive AI platform that extends beyond coronary artery calcification to include robust analysis for lung pathologies such as lung cancer and COPD. This solution is best suited for practices needing a multi-faceted diagnostic tool that integrates CAC scoring with lung nodule detection, emphysema quantification, and ILD pattern analysis from CT scans, streamlining a broader range of cardiothoracic diagnostic workflows.

View AVIEW →

When choosing between Imbio’s CAC Software and Coreline Soft’s AVIEW, physicians should consider their primary diagnostic focus and workflow integration needs. Imbio’s CAC Software is a specialized tool, excelling in the automated post-processing of non-contrast chest CTs specifically for coronary artery calcification (CAC) analysis. It provides detailed quantification, including Agatston scores, arterial age, and calcified lesion mass and volume, along with 3D visualizations, making it ideal for cardiologists and radiologists primarily focused on precise CAC assessment and cardiovascular risk stratification.

The key practical difference lies in AVIEW’s broader diagnostic scope. While AVIEW also offers robust CAC scoring (Agatston, volume, mass score, and risk stratification), it extends its capabilities to comprehensive lung analysis, including AI-powered lung nodule detection and characterization, emphysema quantification, and interstitial lung disease pattern analysis. This makes AVIEW a more versatile platform for radiologists and pulmonologists who require a single solution for both cardiac and pulmonary assessments from CT scans, streamlining workflows for multiple conditions.

Therefore, a physician whose practice heavily emphasizes cardiovascular risk assessment through CAC scoring and desires a highly focused, deep-learning based tool for this specific purpose would likely find Imbio’s CAC Software more suitable. Conversely, a physician or department seeking an integrated AI platform that can handle a wider range of diagnostic tasks across cardiology and pulmonology, including lung cancer screening and COPD assessment in addition to CAC, would benefit more from Coreline Soft’s AVIEW due to its comprehensive multi-organ analysis capabilities and workflow automation features.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature CAC Software AVIEW
Pricing Contact for pricing Subscription; one-off payment
Deployment Cloud, On-premise, Partner platforms Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status 1 AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW

Tool B offers broader workflow automation, including features like follow-up registration and nodule matching for serial CT scans, and the ability to generate patient-facing reports. It also supports access via mobile devices and web browsers, indicating a more comprehensive and flexible user experience. While Tool A is highly automated for its specific function, Tool B's features suggest a wider range of usability enhancements across various tasks and access points.

Clinical Value

AVIEW

Tool B provides significantly broader clinical value by offering AI-powered detection, diagnosis, and monitoring for multiple major thoracic diseases, including lung cancer, COPD, and Interstitial Lung Disease (ILD), in addition to coronary artery calcification. This multi-disease capability from a single CT scan offers greater comprehensive utility compared to Tool A's sole focus on CAC quantification.

Pricing & Value

AVIEW

Tool B offers greater transparency by explicitly outlining its pricing models, including subscription and one-off payment options, and detailing that pricing is based on the number of installations and users. Tool A, in contrast, requires direct contact for pricing, which provides less immediate information for potential buyers.

Enterprise Readiness

CAC Software

Both tools are FDA cleared and HIPAA compliant, offering flexible deployment options including cloud and on-premise solutions. However, Tool A explicitly states it 'has_baa': '1' (Business Associate Agreement), which is a crucial legal and compliance assurance for enterprise healthcare deployments, giving it a slight edge in this dimension.

Innovation

AVIEW

Tool B demonstrates broader innovation by applying deep learning across a wider spectrum of complex thoracic imaging challenges, including multi-disease detection (lung cancer, COPD, ILD, CAC) and advanced segmentation of multiple anatomical structures. Its mention of 'CT kernel conversion AI technology' and ability to analyze 'Big 3 diseases from a single examination' highlight a more expansive and integrated approach to AI in medical imaging.

Support & Docs

CAC Software

Tool A provides clear and accessible support channels, including phone, email, and an online case submission form with specified support hours. While Tool B offers comprehensive product catalogs and technical documentation, its direct support contact information and structured support process are not as readily apparent in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature CAC Software AVIEW
Name CAC Software AVIEW
Company Imbio Coreline Soft Co.
Primary Focus Automated image post-processing for coronary artery calcification from non-contrast chest CT. Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Categories Cardiology AI Cardiology AI, Oncology AI, Radiology & Imaging AI
Specialties Cardiology, Radiology Cardiology, Pulmonology, Radiology
CAC Specific Outputs/Features Outputs Agatston score, arterial age, calcified lesion mass and volume; Provides 3D visualizations and annotated images. CAC scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of coronary arteries; 3D visualizations and comprehensive PDF reports.

Videos

Demos, reviews, and walkthroughs featuring CAC Software and AVIEW.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Imbio's CAC Software is specifically designed for automated post-processing of non-contrast chest CTs to help determine the location and quantify coronary artery calcification. In contrast, Coreline Soft's AVIEW is a more comprehensive AI platform that offers solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Imbio's CAC Software outputs the Agatston score, arterial age, and calcified lesion mass and volume. Coreline Soft's AVIEW also provides Agatston, volume, and mass scores, along with risk stratification for coronary artery calcification.
Imbio's CAC Software focuses solely on coronary artery calcification analysis and does not include lung analysis features. Coreline Soft's AVIEW, however, offers extensive lung capabilities such as AI-powered lung nodule detection and characterization, emphysema quantification, and interstitial lung disease (ILD) pattern analysis.
Imbio's CAC Software integrates into existing DICOM viewing workflows. Coreline Soft's AVIEW platform offers broader integration with PACS, RIS, and CIS, and also includes features for follow-up registration and nodule matching for serial CT scans.
AI Tool Finder
AI-powered search. Results may not be comprehensive.